Merck & Co., Inc. (NYSE:MRK) Trading 0.5% Higher – Time to Buy?

by · The Markets Daily

Merck & Co., Inc. (NYSE:MRK – Get Free Report)’s stock price rose 0.5% during trading on Monday . The stock traded as high as $102.28 and last traded at $101.65. Approximately 2,715,183 shares were traded during mid-day trading, a decline of 71% from the average daily volume of 9,256,337 shares. The stock had previously closed at $101.19.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Bank of America restated a “buy” rating and set a $121.00 price objective on shares of Merck & Co., Inc. in a research note on Tuesday, December 10th. Wolfe Research initiated coverage on shares of Merck & Co., Inc. in a research note on Friday, November 15th. They issued a “peer perform” rating for the company. Daiwa America downgraded shares of Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 11th. Daiwa Capital Markets downgraded shares of Merck & Co., Inc. from a “buy” rating to a “neutral” rating in a research report on Monday, November 11th. Finally, BMO Capital Markets reduced their price target on shares of Merck & Co., Inc. from $150.00 to $136.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $129.20.

Read Our Latest Stock Analysis on Merck & Co., Inc.

Merck & Co., Inc. Stock Down 1.1 %

The firm has a 50 day simple moving average of $103.26 and a two-hundred day simple moving average of $114.81. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.15 and a current ratio of 1.36. The stock has a market cap of $253.12 billion, a P/E ratio of 21.31, a P/E/G ratio of 1.43 and a beta of 0.39.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its earnings results on Thursday, October 31st. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $1.50 by $0.07. The firm had revenue of $16.66 billion for the quarter, compared to analysts’ expectations of $16.47 billion. Merck & Co., Inc. had a net margin of 19.23% and a return on equity of 36.42%. Merck & Co., Inc.’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter last year, the company earned $2.13 EPS. Equities research analysts predict that Merck & Co., Inc. will post 7.73 earnings per share for the current year.

Merck & Co., Inc. Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 8th. Stockholders of record on Monday, December 16th will be paid a $0.81 dividend. This represents a $3.24 dividend on an annualized basis and a dividend yield of 3.24%. The ex-dividend date is Monday, December 16th. This is an increase from Merck & Co., Inc.’s previous quarterly dividend of $0.77. Merck & Co., Inc.’s payout ratio is currently 64.57%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Wellington Management Group LLP grew its stake in shares of Merck & Co., Inc. by 4.6% in the 3rd quarter. Wellington Management Group LLP now owns 75,809,383 shares of the company’s stock worth $8,608,914,000 after purchasing an additional 3,327,404 shares during the last quarter. International Assets Investment Management LLC increased its holdings in shares of Merck & Co., Inc. by 11,876.3% in the third quarter. International Assets Investment Management LLC now owns 2,971,554 shares of the company’s stock valued at $337,450,000 after buying an additional 2,946,742 shares in the last quarter. Two Sigma Advisers LP increased its holdings in shares of Merck & Co., Inc. by 157.9% in the third quarter. Two Sigma Advisers LP now owns 4,264,100 shares of the company’s stock valued at $484,231,000 after buying an additional 2,610,800 shares in the last quarter. Wulff Hansen & CO. lifted its position in shares of Merck & Co., Inc. by 11,860.9% during the 2nd quarter. Wulff Hansen & CO. now owns 2,494,199 shares of the company’s stock valued at $308,782,000 after acquiring an additional 2,473,346 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec grew its holdings in shares of Merck & Co., Inc. by 68.7% in the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 5,388,551 shares of the company’s stock worth $611,924,000 after acquiring an additional 2,194,463 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Company Profile

(Get Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

See Also